Summary
232.44 0.05(0.02%)11/06/2024
Penumbra Inc (PEN)
Penumbra Inc (PEN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.02 | 10.07 | 21.82 | 35.22 | 9.84 | 16.99 | 39.99 | 462.81 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 232.44 | |
| Open | 238.90 | |
| High | 238.90 | |
| Low | 228.90 | |
| Volume | 219,892 | |
| Change | 0.05 | |
| Change % | 0.02 | |
| Avg Volume (20 Days) | 360,564 | |
| Volume/Avg Volume (20 Days) Ratio | 0.61 | |
| 52 Week Range | 148.16 - 277.34 | |
| Price vs 52 Week High | -16.19% | |
| Price vs 52 Week Low | 56.88% | |
| Range | -2.70 | |
| Gap Up/Down | 3.51 | |
Fundamentals | ||
| Market Capitalization (Mln) | 7,444 | |
| EBIDTA | 53,224,000 | |
| PE Ratio | 275.3667 | |
| PEG Ratio | -62.2700 | |
| WallStreet Target Price | 329.83 | |
| Book Value | 18.8420 | |
| Earnings Per Share | 0.9000 | |
| EPS Estimate Current Quarter | 0.1600 | |
| EPS Estimate Next Quarter | 0.2300 | |
| EPS Estimate Current Year | 0.8200 | |
| EPS Estimate Next Year | 1.4200 | |
| Diluted EPS (TTM) | 0.9000 | |
| Revenues | ||
| Profit Marging | 0.0472 | |
| Operating Marging (TTM) | 0.0565 | |
| Return on asset (TTM) | 0.0281 | |
| Return on equity (TTM) | 0.0458 | |
| Revenue TTM | 710,476,992 | |
| Revenue per share TTM | 19.4700 | |
| Quarterly Revenue Growth (YOY) | 0.2580 | |
| Quarterly Earnings Growth (YOY) | 7.0000 | |
| Gross Profit (TTM) | 356,575,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 275.3667 | |
| Forward PE | 212.7660 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 13.2443 | |
| Revenue Enterprise Value | 12.7495 | |
| EBITDA Enterprise Value | 201.6340 | |
| Shares | ||
| Shares Outstanding | 37,358,800 | |
| Shares Float | 35,139,654 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 4.41 | |
| Institutions (%) | 80.93 | |
11/05 13:46 EST - zacks.com
Here is Why Growth Investors Should Buy Penumbra (PEN) Now
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here is Why Growth Investors Should Buy Penumbra (PEN) Now
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
11/05 10:51 EST - zacks.com
Here's Why Penumbra (PEN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Penumbra (PEN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
11/05 09:00 EST - prnewswire.com
New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options
Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system ALAMEDA, Calif. , Nov. 5, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra's computer assisted vacuum thrombectomy (CAVT™) technology have a shorter length of hospital stay, shorter post-procedure length of stay and fewer complications when compared to other treatment options.
New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options
Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system ALAMEDA, Calif. , Nov. 5, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra's computer assisted vacuum thrombectomy (CAVT™) technology have a shorter length of hospital stay, shorter post-procedure length of stay and fewer complications when compared to other treatment options.
10/31 09:50 EST - zacks.com
Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market
The third-quarter results reflect another strong performance by Penumbra's U.S. thrombectomy business.
Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market
The third-quarter results reflect another strong performance by Penumbra's U.S. thrombectomy business.
10/30 23:45 EST - seekingalpha.com
Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript
Penumbra, Inc. (NYSE:PEN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman and Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Richard Newitter - Truist Securities Robert Marcus - JPMorgan Joanne Wuensch - Citi Michael Sarcone - Jefferies Samantha Kurtz - Piper Sandler Michael Kratky - Leerink Pito Chickering - Deutsche Bank Michael Matson - Needham Operator Good afternoon. My name is Jeremy, and I will be your conference operator today.
Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript
Penumbra, Inc. (NYSE:PEN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman and Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Richard Newitter - Truist Securities Robert Marcus - JPMorgan Joanne Wuensch - Citi Michael Sarcone - Jefferies Samantha Kurtz - Piper Sandler Michael Kratky - Leerink Pito Chickering - Deutsche Bank Michael Matson - Needham Operator Good afternoon. My name is Jeremy, and I will be your conference operator today.
10/30 19:36 EST - zacks.com
Penumbra (PEN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Penumbra (PEN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Penumbra (PEN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Penumbra (PEN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
10/30 18:31 EST - zacks.com
Penumbra (PEN) Q3 Earnings and Revenues Top Estimates
Penumbra (PEN) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.67 per share a year ago.
Penumbra (PEN) Q3 Earnings and Revenues Top Estimates
Penumbra (PEN) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.67 per share a year ago.
10/30 16:05 EST - prnewswire.com
Penumbra, Inc. Reports Third Quarter 2024 Financial Results
ALAMEDA, Calif. , Oct. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2024.
Penumbra, Inc. Reports Third Quarter 2024 Financial Results
ALAMEDA, Calif. , Oct. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2024.
10/23 11:06 EST - zacks.com
Penumbra (PEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra (PEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10/14 18:20 EST - fool.com
Why Penumbra Stock Zoomed 4% Higher Today
The latest news from the lab, plus an analyst's bullish move, combined to put some zip in the company's shares.
Why Penumbra Stock Zoomed 4% Higher Today
The latest news from the lab, plus an analyst's bullish move, combined to put some zip in the company's shares.
10/14 09:00 EST - prnewswire.com
Penumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke
ALAMEDA, Calif. , Oct. 14, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic stroke.
Penumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke
ALAMEDA, Calif. , Oct. 14, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic stroke.
10/09 09:48 EST - zacks.com
Here's Why You Should Retain Penumbra Stock in Your Portfolio Now
Investors feel optimistic about PEN's strong growth prospects in the Thrombectomy business. Yet, unfavorable forex impacts are concerning.
Here's Why You Should Retain Penumbra Stock in Your Portfolio Now
Investors feel optimistic about PEN's strong growth prospects in the Thrombectomy business. Yet, unfavorable forex impacts are concerning.
10/02 16:30 EST - prnewswire.com
Penumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024
ALAMEDA, Calif. , Oct. 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024 at 4:30 PM Eastern Time.
Penumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024
ALAMEDA, Calif. , Oct. 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024 at 4:30 PM Eastern Time.
09/24 12:47 EST - zacks.com
ITGR vs. PEN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Instruments stocks have likely encountered both Integer (ITGR) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
ITGR vs. PEN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Instruments stocks have likely encountered both Integer (ITGR) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
09/18 18:29 EST - fool.com
Why Penumbra Stock Zoomed Nearly 5% Higher Today
A researcher initiated coverage of the medical device maker with a confident buy recommendation. He sees multiple positive factors that should propel its growth.
Why Penumbra Stock Zoomed Nearly 5% Higher Today
A researcher initiated coverage of the medical device maker with a confident buy recommendation. He sees multiple positive factors that should propel its growth.
09/17 09:15 EST - zacks.com
PEN Stock to Gain From CE Mark Approval for its CAVT Technologies
Penumbra receives the CE Mark approval for Lightning Flash 2.0 and Lightning Bolt 7 in Europe.
PEN Stock to Gain From CE Mark Approval for its CAVT Technologies
Penumbra receives the CE Mark approval for Lightning Flash 2.0 and Lightning Bolt 7 in Europe.
09/16 03:00 EST - prnewswire.com
Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash™ 2.0 and Lightning Bolt™ 7 - in Europe
Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed to restore blood flow quickly Lightning Flash™ 2.0 will be the most advanced thrombectomy system on the European market to address venous and pulmonary thrombus Lightning Bolt™ 7 is designed to enhance the ability to rapidly remove blood clots in the arteries with modulated aspiration, addressing conditions such as acute limb ischemia (ALI), hibernating thrombus and visceral occlusions ALAMEDA, Calif. , Sept. 16, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for the latest computer assisted vacuum thrombectomy (CAVT) technologies – Lightning Flash™ 2.0 and Lightning Bolt™ 7.
Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash™ 2.0 and Lightning Bolt™ 7 - in Europe
Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed to restore blood flow quickly Lightning Flash™ 2.0 will be the most advanced thrombectomy system on the European market to address venous and pulmonary thrombus Lightning Bolt™ 7 is designed to enhance the ability to rapidly remove blood clots in the arteries with modulated aspiration, addressing conditions such as acute limb ischemia (ALI), hibernating thrombus and visceral occlusions ALAMEDA, Calif. , Sept. 16, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for the latest computer assisted vacuum thrombectomy (CAVT) technologies – Lightning Flash™ 2.0 and Lightning Bolt™ 7.
09/04 12:41 EST - zacks.com
TFX or PEN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
TFX or PEN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
08/29 12:37 EST - zacks.com
Why Is Penumbra (PEN) Up 20% Since Last Earnings Report?
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
Why Is Penumbra (PEN) Up 20% Since Last Earnings Report?
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
08/27 16:30 EST - prnewswire.com
Penumbra, Inc. to Present at the Baird Global Healthcare Conference
ALAMEDA, Calif. , Aug. 27, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 10, 2024.
Penumbra, Inc. to Present at the Baird Global Healthcare Conference
ALAMEDA, Calif. , Aug. 27, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 10, 2024.